EQ-5D
EQ5DMAP: a command for mapping between EQ-5D-3L and EQ-5D-5L
24
Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis
14
Estimating an EQ-5D population value set: the case of Japan
43
Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis
41
Copula-based modelling of self-reported health states An application to the use of EQ-5D-3L and EQ-5D-5L in evaluating drug therapies for rheumatic disease
40
Adjustment of foreign EQ-5D-3L utilities can increase their transferability
8
EQ-5D-5L norms for the urban Chinese population in China
9
Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV
14
A review of the psychometric performance of the EQ-5D in people with urinary incontinence
14
Preparatory study for the revaluation of the EQ-5D tariff: methodology report
222
Modelling the relationship between the WOMAC osteoarthritis index and EQ-5D
6
Outcome assessment after hip fracture : is EQ 5D the answer?
8
A comparison of the EQ-5D and the SF-6D across seven patient groups
13
A review of health utilities using the EQ-5D in studies of cardiovascular disease
12
Validity and reliability of EQ-5D-3L for breast cancer patients in Korea
7
Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients
10
Evaluation of health-related quality of life using EQ-5D in Takamatsu, Japan
11
The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis
7
Fitting adjusted limited dependent variable mixture models to EQ-5D
16
Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease
9